Lamotrigine Augmentation of Serotonin Reuptake Inhibitors in Severe and Long-Term Treatment-Resistant Obsessive-Compulsive Disorder
The treatment recommendations in obsessive-compulsive disorder (OCD) after lack of response to selective serotonin reuptake inhibitors (SSRIs) include augmentation with other drugs, particularly clomipramine, a more potent serotonin reuptake inhibitor (SRI), or antipsychotics. We present two cases o...
Saved in:
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | Case Reports in Psychiatry |
Online Access: | http://dx.doi.org/10.1155/2013/612459 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832557010088886272 |
---|---|
author | Manuel Arrojo-Romero María Tajes Alonso Jose de Leon |
author_facet | Manuel Arrojo-Romero María Tajes Alonso Jose de Leon |
author_sort | Manuel Arrojo-Romero |
collection | DOAJ |
description | The treatment recommendations in obsessive-compulsive disorder (OCD) after lack of response to selective serotonin reuptake inhibitors (SSRIs) include augmentation with other drugs, particularly clomipramine, a more potent serotonin reuptake inhibitor (SRI), or antipsychotics. We present two cases of response to lamotrigine augmentation in treatment-refractory OCD; each received multiple SRI trials over a >10-year period. The first patient had eleven years of treatment with multiple combinations including clomipramine and SSRIs. She had a >50% decrease of Y-BOCS (from 29 to 14) by augmenting paroxetine (60 mg/day) with lamotrigine (100 mg/day). The second patient had 22 years of treatment with multiple combinations, including combinations of SSRIs with clomipramine and risperidone. She had an almost 50% decrease of Y-BOCS (from 30 to 16) and disappearance of tics by augmenting clomipramine (225 mg/d) with lamotrigine (200 mg/day). These two patients were characterized by lack of response to multiple treatments, making a placebo response to lamotrigine augmentation unlikely. Prospective randomized trials in treatment-resistant OCD patients who do not respond to combinations of SSRIs with clomipramine and/or antipsychotics are needed, including augmentation with lamotrigine. Until these trials are available, our cases suggest that clinicians may consider lamotrigine augmentation in such treatment-resistant OCD patients. |
format | Article |
id | doaj-art-327e5ef712e44c2fb403562b090a40a9 |
institution | Kabale University |
issn | 2090-682X 2090-6838 |
language | English |
publishDate | 2013-01-01 |
publisher | Wiley |
record_format | Article |
series | Case Reports in Psychiatry |
spelling | doaj-art-327e5ef712e44c2fb403562b090a40a92025-02-03T05:43:44ZengWileyCase Reports in Psychiatry2090-682X2090-68382013-01-01201310.1155/2013/612459612459Lamotrigine Augmentation of Serotonin Reuptake Inhibitors in Severe and Long-Term Treatment-Resistant Obsessive-Compulsive DisorderManuel Arrojo-Romero0María Tajes Alonso1Jose de Leon2Department of Psychiatry, Complejo Hospitalario Universitario, 15701 Santiago de Compostela, SpainDepartment of Psychiatry, Complejo Hospitalario Universitario, 15701 Santiago de Compostela, SpainMental Health Research Center, Eastern State Hospital, Lexington, KY 40508, USAThe treatment recommendations in obsessive-compulsive disorder (OCD) after lack of response to selective serotonin reuptake inhibitors (SSRIs) include augmentation with other drugs, particularly clomipramine, a more potent serotonin reuptake inhibitor (SRI), or antipsychotics. We present two cases of response to lamotrigine augmentation in treatment-refractory OCD; each received multiple SRI trials over a >10-year period. The first patient had eleven years of treatment with multiple combinations including clomipramine and SSRIs. She had a >50% decrease of Y-BOCS (from 29 to 14) by augmenting paroxetine (60 mg/day) with lamotrigine (100 mg/day). The second patient had 22 years of treatment with multiple combinations, including combinations of SSRIs with clomipramine and risperidone. She had an almost 50% decrease of Y-BOCS (from 30 to 16) and disappearance of tics by augmenting clomipramine (225 mg/d) with lamotrigine (200 mg/day). These two patients were characterized by lack of response to multiple treatments, making a placebo response to lamotrigine augmentation unlikely. Prospective randomized trials in treatment-resistant OCD patients who do not respond to combinations of SSRIs with clomipramine and/or antipsychotics are needed, including augmentation with lamotrigine. Until these trials are available, our cases suggest that clinicians may consider lamotrigine augmentation in such treatment-resistant OCD patients.http://dx.doi.org/10.1155/2013/612459 |
spellingShingle | Manuel Arrojo-Romero María Tajes Alonso Jose de Leon Lamotrigine Augmentation of Serotonin Reuptake Inhibitors in Severe and Long-Term Treatment-Resistant Obsessive-Compulsive Disorder Case Reports in Psychiatry |
title | Lamotrigine Augmentation of Serotonin Reuptake Inhibitors in Severe and Long-Term Treatment-Resistant Obsessive-Compulsive Disorder |
title_full | Lamotrigine Augmentation of Serotonin Reuptake Inhibitors in Severe and Long-Term Treatment-Resistant Obsessive-Compulsive Disorder |
title_fullStr | Lamotrigine Augmentation of Serotonin Reuptake Inhibitors in Severe and Long-Term Treatment-Resistant Obsessive-Compulsive Disorder |
title_full_unstemmed | Lamotrigine Augmentation of Serotonin Reuptake Inhibitors in Severe and Long-Term Treatment-Resistant Obsessive-Compulsive Disorder |
title_short | Lamotrigine Augmentation of Serotonin Reuptake Inhibitors in Severe and Long-Term Treatment-Resistant Obsessive-Compulsive Disorder |
title_sort | lamotrigine augmentation of serotonin reuptake inhibitors in severe and long term treatment resistant obsessive compulsive disorder |
url | http://dx.doi.org/10.1155/2013/612459 |
work_keys_str_mv | AT manuelarrojoromero lamotrigineaugmentationofserotoninreuptakeinhibitorsinsevereandlongtermtreatmentresistantobsessivecompulsivedisorder AT mariatajesalonso lamotrigineaugmentationofserotoninreuptakeinhibitorsinsevereandlongtermtreatmentresistantobsessivecompulsivedisorder AT josedeleon lamotrigineaugmentationofserotoninreuptakeinhibitorsinsevereandlongtermtreatmentresistantobsessivecompulsivedisorder |